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We have developed a protocol for generating genome-wide maps (meiomaps) of 
recombination and chromosome segregation for the three products of human female 
meiosis: the first and second polar bodies (PB1 and PB2) and the corresponding 
oocyte. PB1 is biopsied and the oocyte is artificially activated by exposure to calcium 
ionophore, after which PB2 is biopsied and collected with the corresponding oocyte. 
The whole genome of the polar bodies and oocytes are amplified by multiple 
displacement amplification and together with maternal genomic DNA are genotyped 
for approximately 300,000 SNPs genome-wide by microarray. Informative maternal 
heterozygous SNPs are phased using a haploid PB2 or oocyte as a reference. A 
simple algorithm is then used to identify the maternal haplotypes for each 
chromosome, in all of the products of meiosis for each oocyte. This allows mapping 
of crossovers and analysis of chromosome segregation patterns. The protocol takes 
a minimum of 3-5 days and requires a clinical embryologist with micromanipulation 
experience and a molecular biologist with basic bioinformatic skills. It has several 
advantages over previous methods; importantly, the use of artificial oocyte activation 
avoids the creation of embryos for research purposes. Also, compared with next 
generation sequencing, targeted SNP genotyping is cost effective and simplifies the 
bioinformatic analysis, since only one haploid reference sample is required to 
establish phase for maternal haplotyping. Finally, meiomapping is more informative 
than copy number analysis alone for analysis of chromosome segregation patterns 
and using this protocol, we have provided new insights that may lead to 







Chromosome segregation errors in human female meiosis are the principal cause of 
embryo aneuploidy leading to pregnancy loss, abnormal pregnancies and live births 
affected by chromosomal disorders1. The causes of these errors are not completely 
understood however, they increase exponentially with maternal age over 35 years 
and are associated with reduced and/or altered patterns of genetic recombination2. 
The evidence for this has been based largely on population studies and analysis of 
genetic markers in trisomic pregnancies and live births2. Furthermore, analysis of 
markers close to the centromere in common trisomies, for example, trisomy 21, 
which causes Down syndrome, has demonstrated the presence of both maternal 
homologues in most cases. Classically, therefore, most trisomies were thought to 
arise by non-disjunction of the bivalent chromosomes in the first meiotic division 
(meiosis I) of oogenesis. 
 
The use of in vitro fertilisation (IVF) for the treatment of infertility opened up the 
possibility of studying these processes directly in human gametes and early 
preimplantation embryos. Early pioneering studies by Angell and colleagues, in 
which human oocytes at various stages were karyotyped, indicated that rather than 
whole chromosome non-disjunction, premature separation of sister chromatids 
(PSSC) at meiosis I was the major mechanism causing segregation errors3. 
However, karyotyping oocytes and embryo cells is technically challenging and 
identification of chromosomes by banding patterns is generally not possible. More 
recently, the development of methods for whole genome amplification from single or 
small numbers of cells biopsied from preimplantation embryos and array based 
comparative genomic hybridisation (array CGH) has allowed chromosome copy 
number analysis for all 23 pairs of chromosomes. Copy number analysis by array 
CGH of all three products of female meiosis, the first and second polar bodies (PB1 
and PB2) and the corresponding fertilised oocyte, demonstrated a high incidence of 
aneuploidy in the oocytes of women of advanced maternal age4. It also confirmed 
that the predominant mechanism causing segregation errors in meiosis I for all 




Whole genome amplification at the single cell level also allows the use of other 
genomics methods including single nucleotide polymorphism (SNP) microarrays and 
next generation sequencing (NGS). Genome-wide SNP genotyping of both parents 
and a close relative of known disease status, allows informative parental SNPs to be 
phased and compared to the genotype of embryo biopsy samples as a universal 
linkage-based test (karyomapping) for preimplantation genetic diagnosis (PGD) of 
single gene defects5,6. Since karyomapping maps the parental origin of each 
chromosome present in the embryo cell(s), meiotic trisomies, monosomies and 
deletions can be detected by the presence or absence of one or both parental 
chromosome haplotypes. Furthermore, the transitions between parental haplotypes 
distal from the centromeres provided the first high resolution data for meiotic 
recombination at the single cell level5. 
 
To identify recombination events at the chromatid level and analyse chromosome 
segregation errors in human oocytes, requires maternal haplotype analysis of all 
three products of meiosis i.e. PB1, PB2 and the oocyte (collectively referred to as 
µRRF\WH-3%WULRV¶)LJ+HUHZHGHVFULEHa protocol for: the artificial activation of 
donated human oocytes, which causes the resumption and completion of meiosis II 
and avoids the need to create fertilised embryos for research purposes;  the biopsy 
of PB1 and PB2 before and after activation and the isolation of the activated oocyte 
(Fig 2); whole genome amplification and genome-wide SNP genotyping; and 
maternal haplotype analysis using a simple algorithm based on Mendelian 
segregation of maternal SNP alleles (meiomapping), similar in principle to 
karyomapping, to generate genome-wide maps of recombination in oocyte-PB trios.  
Using this protocol, we recently demonstrated selection for maternal recombination 
rates, described a novel reverse segregation pattern of chromosome segregation 
and presented the first evidence for meiotic drive7. 
 
Development of the protocol 
The meiomap protocol was developed as a tool to study recombination and 
chromosome segregation in human female meiosis. A previous method used 
donated oocytes, which were fertilised by intracytoplasmic sperm microinjection 
(ICSI) using donated sperm, following biopsy of PB18. After PB2 biopsy, the male 
and female pronucleus were removed by micromanipulation and the whole genome 
  
of the polar bodies and female pronucleus (FPN) were amplified by Multiple 
Annealing and Looping Based Amplification Cycles (MALBAC). Maternal haplotyping 
was then achieved by NGS and bioinformatic analysis of multiple triads. 
 
To avoid the ethical issues involved in creating fertilised embryos for research 
purposes and the additional manipulation required to remove the pronuclei, we 
based our protocol on an established method for artificial activation of oocytes 
arrested in metaphase of the second meiotic division (MII) with calcium ionophore 
(A23187)9-14. The activated MII oocytes resume meiosis and extrude the PB2. 
Furthermore, artificial activation has been used clinically in cases of ICSI failure and 
live births reported15-19. Sources of human oocytes may include cryopreserved 
oocytes no longer required for therapeutic use or theoretically, immature oocytes, at 
germinal vesicle or metaphase of the first meiotic division (MI), matured in vitro to 
MII. These are widely available, since a proportion of oocytes at these stages are 
collected in routine IVF cycles. Irrespective of the source of oocytes, informed patient 
or donor consent is mandatory. 
 
Our choice of method for whole genome amplification was based on the availability 
of commercial PCR-based libraries and multiple displacement amplification (MDA) 
methods are used routinely for chromosome copy number analysis by array CGH or 
NGS, and for karyomapping by SNP genotyping. However, for SNP genotyping the 
call rates are higher and the resulting resolution of the meiomap analysis is also 
higher with MDA. Finally, targeted sequencing of a defined set of SNPs using a 
microarray is cost effective and simplifies the bioinformatic analysis since the same 
loci are analysed in the maternal DNA and oocyte-PB trios. 
 
To map the positions of crossovers in the oocyte-PB trios, an algorithm is used to 
phase heterozygous maternal SNPs distributed across each chromosome (including 
the non-pseudoautosomal region of the X chromosome and excluding the Y 
chromosome) using a haploid PB2 or activated oocyte as a reference. This results in 
two notional maternal haplotypes at consecutive loci across each chromosome: 
Maternal haplotype 1 and 2 colour coded in yellow and green, respectively (Table 1). 
The genotypes at all of these informative loci are then examined in each of the other 
trio samples and compared to the reference. If the sample genotype is homozygous 
  
and identical to the reference it is Maternal haplotype 1 (yellow). If homozygous for 
the other SNP allele then it is Maternal haplotype 2 (green). Finally, if heterozygous it 
is colour coded in blue or if neither haplotype is detected for that SNP this is depicted 
in grey (Table 1 & Figure 3). Occasionally, heterozygous SNPs call in homozygous 
(haploid) regions anGZHUHIHUWRWKHVHDVµDOOHOHGURSLQ¶$', events that generate 
low-OHYHOEDFNJURXQGµQRLVH¶LQWKHGDWD (e.g. Table 1: SNP 13 in PB2). Please note 
that because the SNP genotyping software assumes that all samples are diploid, it 
calls haploid SNP loci LQ3%RUWKHDFWLYDWHGRRF\WHDVHLWKHUµ$$¶RUµ%%¶:H
WKHUHIRUHUHIHUKHUHWRWKHVHFDOOVDVµKRPR]\JRXV¶WRGLVWLQJXLVKWKHVHORFLIURP
genuinely heterozygous calls in, for example, PB1 where two chromatid regions from 
both maternal homologues are present. 
 
Theoretically, all maternal heterozygous SNPs should be informative. In practice, 
however, selecting heterozygous maternal SNPs, which are, as an additional 
requirement, genotyped as homozygous in the chosen reference, significantly 
improves the consistency of haplotype calling. (Please note that because of the 
principle of independent segregation, each chromosome in the reference has a 
random grandparental origin). 
 
When the colour coded SNPs are displayed in columns as a consecutive series for 
each chromosome, the transitions which occur as a result of recombination (or 
µFURVVRYHUV¶ are evident (Figure 3). For PB1, each recombination is marked by a 
transition from a heterozygous (blue) region to a homozygous region for one of the 
two maternal haplotypes (yellow or green) or vice versa (Figure 4). For PB2 and the 
activated oocyte, the transitions occur between the two homozygous maternal 
haplotypes (yellow to green or green to yellow; Figure 4). At this stage, the reference 
sample, which for phasing purposes is assumed to have no recombination, displays 
only one maternal haplotype i.e. all SNPs coded yellow. However, in most cases the 
reference chromosome will in fact be recombinant. This has the effect of creating an 
apparent recombination in all of the other haploid samples at that position (common 
crossover). This is because each SNP along a chromosome is compared to the 
reference and where they match they are assigned the same haplotype as the 
reference (yellow) and where they differ they are assigned the opposing haplotype 
JUHHQ$UHFRPELQDWLRQLQWKHUHIHUHQFHWKHUHIRUHFDXVHVDµVZLWFK¶ in haplotype at 
  
that position across all other haploid samples from that donor (Figure 3 & 4). Each 
sample, therefore, has a combination of true crossovers and common crossovers. 
Secondary analysis is then required to identify the common crossovers, restore them 
to the reference sample and remove them from all of the others (Figure 4).  
 
Applications of the method 
This protocol is an important advance to human oocyte research within an ethical 
framework that facilitates a new era of investigation into various aspects of female 
meiosis. It does not require the creation or destruction of fertilized human embryos 
and the protocol was paramount to uncovering several novel findings7. These 
include a previously unknown meiotic segregation pattern WHUPHGµUHYHUVH
VHJUHJDWLRQ¶; in which both homologs undergo a meiosis II-like division at meiosis I 
and the two non-sister chromatids segregate at meiosis II7. This work has also shed 
new light on the meiotic origin of both monosomies and trisomies. It has led to direct 
evidence showing that lower, genome-wide recombination rates are associated with 
increased missegregation of chromosomes in human female meiosis, suggesting 
that higher recombination rates are selected for in the female germline7. The studies 
also revealed direct evidence of meiotic drive, in which non-recombinant chromatids 
are preferentially excluded from the oocyte7. This protocol is central for further 
oocyte-PB trio analysis and is being used by the Human MeioMap Project to explore 
human female meiosis on a broader population scale 
(www.sussex.ac.uk/lifesci/hoffmannlab/research/meiomap). 
 
Currently the protocol is optimised for oocytes arrested at metaphase II (MII). 
However, it could also theoretically be applied to surplus immature, germinal vesicle 
(GV) or metaphase I (MI) stage, oocytes from human IVF cycles that are otherwise 
unused and can be matured in vitro to the metaphase stage of the second meiotic 
division. This would require an additional in vitro maturation step of up to 48 hours 
culture before starting the protocol14. Nevertheless, these oocytes represent a 
potentially large resource thatZLWKSDWLHQWV¶LQIRUPHGFRQVHQWcould enable easy 
and ethical access to material for the study of human female meiosis. Application of 




Genome-wide mapping of female meioses can also be achieved by analysing the 
SNP genotype of PB1, PB2 and fertilised embryos (embryo-PB trios). For embryo-
PB trios, however, the presence of the paternal genome in the embryo samples has 
to be taken into account. One option is to genotype both parents and perform 
karyomap analysis5. Unlike meiomap analysis in which all heterozygous maternal 
SNP loci are potentially informative, karyomapping identifies two sets of informative 
SNP loci for the paternal and maternal chromosomes, in which one parent is 
heterozygous and the other homozygous. Heterozygous informative SNPs are then 
phased, typically using a child or, with embryo-PB trios, a sibling embryo, as 
reference and compared to the genotype of each sample. This has the advantage 
that crossovers between the paternal chromosomes can be identified in the same 
embryos. However, the resolution is lower because two distinct sets of informative 
SNPs are used to define the parental haplotypes and the number of these SNP loci 
is significantly reduced. Alternatively, meiomap analysis as described here can be 
used with a PB2 or an embryo as reference, with the additional requirement that both 
the reference and sample SNP genotypes are homozygous. Compared with oocyte-
PB trios, this again reduces the number of informative SNP loci and the resolution, 
but is still effective. For purposes of brevity, we have referred to oocyte-PB trios only 
throughout the protocol since in all other aspects, the protocol is the same. 
  
In theory, meiomapping or karyomapping of polar bodies alone could be used for 
PGD to identify maternal meiotic errors resulting in aneuploidy in the corresponding 
fertilised embryo, to diagnose the inheritance of maternal structural chromosome 
defects or for linkage-based detection of single gene defects. However, neither of 
these protocols have been validated for clinical use and establishing which maternal 
haplotype is associated with a genetic defect is still required. This would require 
some knowledge of familial genotypes, such as the genotype of an affected child or 
relative.  
 
Comparison to other methods: Advantages and Limitations 
Until the introduction of genome-wide sequence analysis8 and meiomapping, studies 
of the relationship between recombination and meiotic chromosome segregation in 
humans were confined to population-based studies20-23. Most of these analyses are 
limited to trisomies that are compatible with in utero development and cannot 
  
ascertain the meiotic origins of monosmies, the vast majority of which do not give 
rise to clinically recognised pregnancies. Furthermore, by only examining one 
product of meiosis; the oocyte (without the information from polar bodies), 
chromosome missegregation patterns and total recombination rates can only be 
estimated.   
 
One major advantage of meiomapping is its power to detect global recombination 
rates in human oocytes. Previously, the only method of detecting recombination 
across all 23 homologs was through cytological analysis of Mlh1 (that marks 
crossovers) in fetal oocytes24,25. However, this method cannot determine crossovers 
that may have arisen through Mlh1-independent pathways (e.g. Mus81-dependent 
crossovers, which account for <10% crossovers 26). Meiomapping provides an 
additional advance over these cytological assessments in that it provides information 
about which of the four chromatids in a bivalent recombined at any given crossover.  
 
The second major advantage of meiomapping is its capacity to reveal the 
chromosome segregation patterns that result in aneuploidy. Previously this could 
only be inferred from pericentromeric SNPs in trisomic conceptions20,27, which are 
potentially subject to interpretation errors. More recently, however, chromosome 
copy number analysis of polar bodies by array CGH has enabled new insight into the 
prevalence of segregation errors in preimplantation embryos following IVF4,28,29.  
Array CGH differs from meiomapping in that it can report chromosome copy number 
losses or gains in the polar bodies, which can in turn reveal any losses/gains in the 
fertilised oocyte, but cannot distinguish maternal haplotypes and therefore whether 
homologs or sister chromatids missegregated.  
 
To obtain similar results to our protocol, Hou et. al used intracytoplasmic sperm 
injection (ICSI) to induce resumption of the second meiotic division in mature (MII 
arrested) human oocytes8. The female pronucleus was then removed from the 
resulting fertilised embryos thus effectively destroying them. Our oocyte activation 
protocol is less technically involved in that the whole oocyte is tubed rather than 
having to use micromanipulation to remove the pronuclei and does not result in the 
creation or destruction of human embryos for research purposes. Furthermore, our 
protocol results in an activation rate equal to or higher than performing ICSI in a 
  
clinical IVF setting30. Hou et. al used a sequencing-based approach8, however, we 
validated our protocol using genome-wide SNP arrays. This protocol is theoretically 
platform-independent, relying only on the detection of genome-wide polymorphisms. 
Therefore, with minor adaptation, the protocol will evolve with advances in single cell 
technology, including next generation sequencing, which has the potential to 
increase resolution. Although our method could be adapted to a sequencing-based 
approach, the efficacy and resolution depends on the read depth and level of SNP 
overlap across all samples (including maternal and reference genotypes). At present, 
the depth of sequencing required for our approach is not cost-effective. 
 
An advantage of our simple Mendelian approach compared to other advanced 
bioinformatic algorithms, which identify haplotypes by analysing multiple reference 
samples8, is that a single haploid reference (PB2 or oocyte) is sufficient to phase 
maternal heterozygous SNPs and detect the majority of recombination events. 
However, the single reference needs to be from a second oocyte-PB trio in order to 
identify all crossover events in the two trios (Table 2). Otherwise, reciprocal 
crossovers between sister chromatids in the bivalent segregating to PB2 and oocyte, 
at precisely the same locus, will not be visible. For optimal detection of all possible 
crossovers three or more oocyte-PB trios are required (Table 2). The identification of 
common crossovers in the second, and at least one other trio, then allows 
assignment of these to the reference sample. Furthermore, availability of multiple 
reference samples can be helpful to resolve rare ambiguous crossovers (for example 
at the extreme ends of chromosomes). It also becomes necessary to use an 
alternative reference if there are one or more aneuploidy or structural chromosome 
abnormalities in the original reference (see Troubleshooting Table 3).  
  
The need to have three or more oocyte trios to detect all of the recombination events 
and chromosome segregation errors is an inherent limitation (Table 2). At present 
the protocol does not allow for the separation of the two sister chromatids in the PB1. 
Reciprocal crossovers in PB1 cannot be detected as they exist in heterozygous 
regions of PB17. Additionally, not all recombination events are visible when 
chromosome segregation errors have taken place. For example, when an extra 
chromatid segregates to the PB1 this will obscure the recombination events on these 
  
three chromatids so that the only detectable recombination event for that bivalent will 
be on the single chromatid in the PB2 or oocyte. 
 
Meiomapping relies upon efficient single cell whole genome amplification (WGA) and 
accurate SNP genotyping. Although the protocol for collection and processing of the 
single cell samples is well established for clinical diagnostic use, amplification failure 
does occasionally occur (<5%) and is highly operator dependent.. Nevertheless, if 
two out of three elements in an oocyte-PB trio are successfully amplified and 
genotyped, all of the recombinations can be identified (owing to the reciprocal nature 
of crossovers). In our initial study, 34 out of 40 (85%) oocytes activated and the 
corresponding trios were amplified but many samples were lost in shipment between 
labs7. Of the remaining samples, all 13 complete oocyte-trios were analysed 
successfully. Also, irrespective of the method used, WGA results in a certain level of 
amplification errors31. Random failure to amplify one of the parental SNP alleles, or 
allele dropout (ADO), for example, is relatively common at the single cell level and 
here results in erroneous homozygous calls in heterozygous regions (Table 1). More 
rarely, allele drop in (ADI) can also occur and result either in erroneous 
heterozygous or homozygous genotype calls. Finally, variation of amplification 
across the genome at the sequence level results in a significantly increased 
proportion of SNPs, ZKLFKFDQQRWEHJHQRW\SHGµQRFDOOs¶DQGORZHURYHUDOOFDOO
rates. These types of errors are particularly evident in heterozygous regions, which 
are typically present in PB1. Indeed, with the beadarray and associated software 
used here, heterozygous calls are much more likely to result in no calls. Overall call 
rates exceeding about 60% are usually satisfactory for meiomapping purposes. 
However, at the lower end of this range, heterozygous regions, whilst easily 
identifiable, have poorly defined boundaries. The location of the crossover is 
therefore best identified from either of the haploid elements (PB2 or oocyte). 
Fortunately, with these ADI is rare and no call rates are also much lower so that the 
transition from one continuous series of SNP alleles for one maternal haplotype, in 
most cases, switches to the next haplotype across adjacent informative SNPs. This 
is reflected in the lower resolution of recombination events in PB1 compared with 
PB2 or oocyte. 
 
  
Further limitations include the distribution of SNP loci genotyped on the array. The 
coverage of the array in this protocol exceeds 90% of the genome. However, there 
are large gaps on the q arms of chromosomes 1 and 9 and recombination in these 
regions requires careful interpretation (See Troubleshooting Table 3). Also, the 
density of SNP markers varies across the genome and consequently so does the 
resolution of the position of recombination events. 
 
Finally, any studies of human oocytes (or embryos) are limited by their restricted 
availability from clinics involved in fertility treatment and legal regulations. They must 
EHHWKLFDOO\VRXUFHGZLWKSDWLHQWV¶LQIRUPHGFRQVHQWSUHIHUDEO\E\WDNHQE\VRPHRQe 
not directly involved in the research. 
 
Experimental Design 
Level of expertise: Access to human oocytes and embryos for research is only 
possible by collaborating with an IVF clinic with suitably qualified personnel and the 
expertise to stimulate the ovaries appropriately and collect the oocytes etc. The 
protocol for meiomapping itself requires a clinical embryologist with 
micromanipulation experience to perform polar body biopsy, activate the oocytes and 
isolate the activated oocytes, and a molecular biologist with basic bioinformatic skills. 
With suitable training, the clinical embryologist can collect the samples and perform 
the whole genome amplification. The amplified DNA can either be sent to a service 
lab for SNP genotyping, or this can be performed in-house if SNP arrays are 
available. Basic bioinformatic skills and knowledge of programming, for example, 
using Visual Basic for Applications (VBA) in Microsoft Excel, is necessary to develop 
the tools to analyse and display the SNP data (see example in Supplementary Data). 
 
Genomic DNA: Genomic DNA from the oocyte donors is obtained by standard 
methods using commercially available kits. Sources of DNA include blood samples, 
buccal cells (kits can be sent in the post to the donors) or cumulus cells removed 




Meiomapping: Informative maternal heterozygous SNP loci are identified and 
phased by reference to the genotype of a haploid PB2 or oocyte. This establishes 
two maternal haplotypes across each chromosome. The genotypes of the polar 
bodies and activated oocytes are then compared to the reference haplotype and 
crossovers identified by transitions between heterozygous and homozygous regions 
(typically in PB1) or between opposing haplotypes in PB1, PB2 or activated oocytes. 
Finally, common crossovers present in all samples are identified and reassigned to 
the reference sample. This reveals the pattern of unique crossover events in the 
oocyte-PB trios, which allows the chromosome segregation patterns to be 
interpreted. 
 
Recombination events can be seen by comparing the samples to a haploid (PB2 or 
oocyte) reference. The reference needs to be from an independent oocyte-PB trio 
from the same donor and ideally with a high call rate (>60%) and low heterozygous 
call rate (~1-2%). The requirement for an independent reference sample 
necessitates at least two oocyte-PB trios per donor. It is desirable to have multiple 
samples from the same donor, which can help overcome problems associated with 
aneuploidy in the reference sample or common crossovers very close to other 
crossovers (see Troubleshooting Table 3 & Table 2). 
Bioinformatics techniques and analysis: The SNP calls for each chromosome 
and each sample are imported into a Microsoft Excel spreadsheet for primary 
analysis (Supplementary Data(DFK613LVFODVVLILHGDVµ$%¶ERWKKDSORW\SHV
µ$$¶RUµ%%¶HDFKJUDQGSDUHQWDOKDSORW\SH5HJLRQVRIKHWHUR]\JRVLW\ERWK
haplotypes present) are defined by the presence of blocks of AB calls. Homozygous 
regions are compared SNP-by-SNP to a reference sample; where the SNPs match 
WKRVHRIWKHUHIHUHQFHWKH\DUHDVVLJQHGµKDSORW\SH¶ (yellow), where they differ 
WKH\DUHµKDSORW\SH¶ (green). This results in a pattern of haplotype switching or 
breakpoints, which represent crossovers. Any crossovers present on the reference 
FKURPDWLGZLOOPDQLIHVWDVµFRPPRQFURVVRYHUV¶DFURVVDOOVDPSOHV)LJXUH	
red boxed region). These are removed and replaced to the reference as part of the 
secondary analysis (see step 48). Chromosome segregation is assessed at the end 
following crossover mapping as part of the secondary analysis. Non-canonical 
segregation patterns manifest as reciprocal losses or gains of chromosomes or 
  
chromatids or in the case of reverse segregation as heterozygous SNPs surrounding 
the centromere in PB1.
  
Materials 
CRITICAL: The reagents and equipment specified below for the culture and 
micromanipulation of human oocytes and embryos are for illustration purposes only. 
Individual IVF clinics will vary in their practices, which are optimised for clinical use.  
 
REAGENTS: 
x Mature (metaphase II arrested) Oocytes 
CAUTION: Any experiments involving human oocytes must conform to relevant 
Institutional and National regulations.  In the UK they must be obtained through an 
HFEA-licensed clinic in accordance with the HFE Act and with approval of the local 
research ethics service. Fully informed patient consent must be obtained in all cases.  
 
x Oocyte culture medium (4XLQQ¶V$GYDQWDJHcleavage medium; Sage, USA, 
ART-1026) 
x Oocyte handling medium (Sage HEPES buffered medium, ART-1023) 
x Human serum albumin (Sage HSA, ART-3001) 
x Mineral oil (Sage culture oil, ART-4008) 
x Hyaluronidase solution (SAGE, ART-4007-A) 
x Phosphate Buffered Saline (PBS) ('XOEHFFR¶V3KRVSKDWH%XIIHUHG6DOLQH
Sigma-Aldrich, USA, D8537) 
x Calcium ionophore (Sigma-Aldrich, USA, A23187)  
x Dimethyl Sulphoxide (DMSO) (Sigma-Aldrich, USA, D2650) 
x WGA Kit (Sure MDA; Illumina, USA, PR-40-405102-00) 
x Genomic DNA from oocyte donors obtained by using any appropriate 
commercially available kit (see Experimental Design for more details) 
 
EQUIPMENT: 
CRITICAL: All equipment should be situated in a dedicated tissue culture facility 
suitable for the culture of human gametes and embryos. 
x Vertical Class 2 flow cabinet work station (IVF Tech, Stenløse DK)  
x Stereo microscope (Leica Microsystems M80, Germany)  
x 37°C heated work surface (IVF Tech, Stenløse DK). 
  
x Incubators for embryo media equilibration and embryo activation culture 
(Sanyo MCO-5M, Sanyo Electric Co. Ltd, Japan- MINC Benchtop incubator, 
COOK Medical, Bloomington USA) 
x Inverted microscope (Nikon Eclipse TE2000-U, Nikon Japan) equipped with 
two micromanipulators (NT-88-V3,Narishige, Japan) fitted with syringes  
attached to the holding and micro-pipettes. 
x Inverted microscope (Nikon IX-70 microscope; Nikon Ltd, Japan) equipped 
with Hoffman Modulation contrast (Nikon Ltd, Japan), 37°C heating stage 
(Tokai Hit Thermo Plate, Tokai Hit CO.Ltd, Japan) and a laser objective 
(Saturn laser 5; Research Instruments, Falmouth UK) 
x Holding micro-pipette (Holding pipette; TPC, Australia)  
x Aspiration micro pipette for biopsy (zona drilling pipette; TPC, Australia) 
x Stripper hand piece and plastic denuding pipette tips with a range of 
GLDPHWHUVȝPȝPDQGȝPOXPHQ)OH[LSHWGHQXGLQJ
pipette,COOK Medical, Ireland) 
x Culture dishes appropriate for culture system, either with or without time lapse 
incubation (EmbryoSlide; Unisense Fertilitech, Denmark/ Vitrolife Göteborg- 
or  Falcon Primaria dish 60x15mm; Corning Incorporated, USA) 
x Biopsy dishes (Nunc IVF ICSI Dish; Thermo Scientific, USA) 
x Karyomapping Beadchip (HumanKaryomap-12 v1.0 BeadChip, Illumina, San 
Diego CA, USA) 
x 0.2ml PCR tubes (any supplier) 
x Thermocycler machine  
x Computer with Visual Basic enabled Microsoft Excel (Microsoft Office; 
Microsoft, USA)  
x OPTIONAL: Time lapse incubator (EmbryoScope; Unisense Fertilitech, 
Denmark/ Vitrolife Göteborg) for embryo cell culture and tracking. 
 
REAGENT SET-UP: 
Calcium ionophore stock solution. Dilute 20.94mg of calcium ionophore in 10ml of 
DMSO to make 4mM stock solution. Store at -20°C for up to 3 months 
  
Working activation culture medium. Add 100ul of calcium ionophore stock solution 
to 3.9ml of Sage cleavage medium for a final 100uM working solution. Add 10% (v/v) 
HSA.  Store at 3-5°C for up to a week. 
Oocyte culture medium. Add 10% HSA to Sage cleavage medium (without calcium 
ionophore). Store at 3-5°C for up to a week.  
Oocyte handling medium.  Add 10% HSA to Sage HEPES buffered media. Store at 
3-5°C for up to a week. 
 
EQUIPMENT SET-UP: 
Oocyte holding dishes: Make two 25µl drops of oocyte culture medium (one for 
washing, one for culture) per oocyte within culture dishes (Falcon Primaria) and 
overlay with mineral oil until the drops are entirely covered. Dishes should be 
allowed to equilibrate in incubator set at 37°C in 6% CO2 and 5% O2 for a minimum 
of 3 hours prior to use and within 24 hours of preparation. 
Activation dishes: Make two 25µl drops of working activation culture medium (one 
for washing, one for culture) per oocyte within culture dishes (Falcon Primaria) and 
overlay with mineral oil until the drops are entirely covered. Dishes should be 
allowed to equilibrate in incubator set at 37°C in 6% CO2 and 5% O2 for a minimum 
of 3 hours prior to use and within 24 hours of preparation. 
Post-activation dishes: This can be done using either EmbryoSlides, if culturing in 
an Embryoscope, or ordinary culture dishes if standard culture is used.If standard 
Culture is used make two 25µl drops of oocyte culture medium (one for washing, one 
for culture) per oocyte within culture dishes (Falcon Primaria) and overlay with 
mineral oil until the drops are entirely covered. If embryoscope culture is used fill all 
12 numbered wells of the EmbryoSlide with 25µl of oocyte culture medium ensuring 
the micro-well at the bottom is free of bubbles. Completely fill the wash wells (with no 
micro-well) with the same medium and overlay with mineral oil until the wells are 
entirely covered. 
Both culture dishes and EmbryoSlides should be allowed to equilibrate in an 
incubator set at 37°C in 6% CO2 and 5% O2 for a minimum of 3 hours prior to use 
and within 24 hours of preparation. 
Biopsy dishes: Make two 10µl drops of oocyte handling medium per oocyte (one 
wash drop, one working drop) within biopsy dishes and overly with mineral oil. Allow 
  
to equilibrate on heated stage (37°C) for a minimum of 20 minutes prior to use an d 
use within one hour.  
  
PROCEDURE:  
CRITICAL: All oocyte culture is performed in a humidified incubator set at 37°C in 
6% CO2 and 5% O2.To enable tracking of the oocytes and their corresponding PBs 
throughout the protocol, individual samples must remain separated. Thus, all culture 
drops, wells and tubes should be uniquely numbered and recorded to allow 
traceability throughout the experiment. 
 
Oocyte preparation TIMING 5-10 mins 
CRITICAL: For best results the protocol should begin 38-40 hours post LH surge 
(natural cycle) or administration of HCG trigger (stimulated cycle).  If using vitrified 
oocytes, the protocol should begin 1-2 hours post oocyte warming (protocol for 
warming will depend on procedure used in clinic. We used the Kitazato CryoTop 
method32).   
 
1. Obtain oocytes collected by surgical means ~35 hours post LH surge (peak of 
circulating Luteinising Hormone) or administration of Human Chorionic 
Gonadotrophin (HCG) injection. Remove all cumulus cell and the cells of the 
corona radiata from the collected oocyte 28. Move all mature MII oocytes to an 
oocyte holding dish containing oocyte culture medium (see reagent set up) 
ready for biopsy and activation. 
CRITICAL STEP: It is imperative to ensure complete removal of surrounding 
cumulus cells before proceeding. Incomplete removal of all maternal somatic 
cells surrounding the oocyte could result in maternal contamination and will be 
apparent in the downstream SNP analysis. We recommend removal of 
cumulus cells by pipetting the oocytes up and down with a 130µm pipette in 
hyaluronidase solution. At this point oocytes may be vitrified for batching 




First polar body (PB1) biopsy. TIMING 15-30 mins 
 
CRITICAL The activation and biopsy part of the protocol (steps 2 to 34) could 
feasibly be performed by a single operator. However, it is recommended that 2 
  
operators work in tandem at time points where certain activities can be performed in 
parallel (e.g. biopsy and tubing) to avoid delays in processing, preserving the 
sample¶VLQWHJULW\, especially when performing the protocol on more than six oocytes 
at the time. The biopsy should be performed as soon as possible following polar 
body extrusion. See troubleshooting table 3 for advice on polar body fragmentation.  
 
2. At a stereo microscope work station, move the prepared oocytes using a 
170um stripper from the culture dish in Step 1 to a biopsy dish (see reagent 
set-up) with individually numbered 10 µl microdrops of HEPES medium + 10% 
HSA under Sage oil. Use the one available wash drop per oocyte to ensure 
that each oocyte is free from any cellular debris by gently pipetting the oocyte 
up and down several times before allocating them to their biopsy working 
drop. The number of oocytes per dish is dependent on the skill of the 
operator. CRITICAL STEP: We recommend that no more than 15 minutes 
should pass between the oocytes entering the dish and  being removed after 
biopsy (from 1-6 oocytes per dish) 
3. Place the biopsy dish containing the oocytes on the inverted microscope (with 
micromanipulators and laser attached) to give a clear view of the PB and 
secure the oocyte by suction with the holding pipette ensuring that the oocyte 
is just above the bottom of the dish (Figure 2A).  
4. Rotate the oocyte using the aspiration pipet until the PB is clearly in focus at 
12 to R¶FORFNIf done correctly, the zona pellucida should also be clearly in 
focus (Figure 2A). CRITICAL STEP: It is essential to maintain a gentle yet 
constantly full seal between the holding pipette and the oocyte as even a 
small break in the seal could result in a poor outcome. 
5. Once the oocyte is correctly positioned for biopsy make a small aperture with 
a series of laser pulses in the zona pellucida, no larger than the diameter of 
the aspiration pipette, adjacent to the PB on the side of the aspiration pipette. 
Work inwards from the outer surface of the zona. CRITICAL STEP: Attention 
must be given so as not to fire a laser pulse at the cytoplasm of the oocyte or 
PB. 
6. Insert the aspiration pipette through the opening in the zona and position the 
lumen of the pipet adjacent to the PB. 
  
7. Use the aspirator to create a small amount of suction and slowly withdraw to 
remove the PB. If the PB is still attached to the oocyte, break the intercellular 
bond using a single laser pulse, on the lowest intensity setting, at the cell 
junction to release the bond. CRITICAL STEP: Ideally the polar body should 
not fully enter the biopsy pipette. The suction created should simply allow the 
polar body to be drawn through the breach in the zona. Complete aspiration of 
the polar body may result in lysis, which may not affect amplification but 
makes tubing unreliable. If PB1 is fragmented during biopsy, ensure all 
fragments are removed for tubing.  
Oocyte activation. TIMING 45-50mins 
8. Move the biopsy dish containing the biopsied oocytes to a stereo microscope 
work station immediately after completing biopsy of all oocytes contained 
within the dish. CRITICAL STEP: Care must be taken during this step 
onwards so as not to exert too much pressure on the biopsied oocytes when 
pipetting. Slow pipetting with gentle aspiration and expulsion is recommended 
using 170um stripper pipettes.  
9. Identify both the PB and the oocyte under the stereo microscope. Use a 
170um stripper pipette to transfer individual oocytes, one at a time, to 
individually numbered drops in an activation culture dish, leaving the biopsied 
PB1 behind in the biopsy dish for immediate tubing.  
10. Use the available wash drops to gently wash each oocyte before allocating 
them to their activation culture drop.  
CRITICAL STEP: care must be taken not to disturb the biopsied polar body when 
removing the oocytes from the biopsy dish. Failure to do so may result in the polar 
body being lost 
11. Begin a 40 minute timer from the time the last oocyte is transferred to the 
activation culture dish and put the dish in the incubator until the 40 minute 
timer ends. 
CRITICAL STEP: At this point, further PB1 biopsy can be performed following Steps 
2-11). If so a second operator should perform the tubing procedure below in parallel. 
 
 
PB1 Tubing. TIMING 15-30mins 
CRITICAL: Prepare liquid nitrogen bath in advance for PB storage 
  
12. Add 1ul of PBS to the appropriate number of 0.2 ml, RNase and DNase free 
thin walled, flat cap PCR tubes for the number of polar bodies and label each 
tube appropriately. 
13. To avoid evaporation and contamination, close the cap on the tubes gently 
(loose cap). CRITICAL STEP: Caps should be closed but easily releasable for 
depositing the samples. The 1uL of PBS should remain at the bottom of the 
tubes. If small drops form on the side of the tube, give the tubes a quick spin 
on the micro centrifuge prior to depositing the samples. 
14. Focus on the polar body from Step 7 with the stereo microscope using the 
mirror to create contrast for best visibility. 
15. Set the stripper pipette to 1uL and using a 120um pipette tip prime as much 
as possible with PBS. Depress the plunger all the way, aspirating PBS into 
the pipette until the plunger is entirely released. CRITICAL STEP: For best 
results change to a new stripper tip for each sample. 
16. Enter the drop with the pipette tip whilst gently expelling a small amount of 
PBS to ensure no oil blocks the tip. No more than 0.5uL should need to be 
expelled.  CRITICAL STEP: If any oil droplets are visible in the pipette tip, try 
to clear it by vigorous aspiration in clean PBS or replace it and restart from 
Step 15. 
17. Place the pipette tip over and adjacent to the PB and release the plunger 
entirely (PB should enter the pipette and remain there). CRITICAL STEP: 
Ensure that the plunger and the pipette are not moved abruptly at this stage 
as the sample could be lost. 
18. Open a pre-primed and labelled PCR tube from Step 12 and hold the tube 
between thumb and index finger so as to have a clear view through the tube 
from top to bottom.  
19. Insert the pipette containing the sample into the tube so that the tip enters the 
PBS. CRITICAL STEP: Avoid touching the sides of the tube or the bottom if 
possible. 
20. Expel the contents of the pipette into the tube stopping when 1uL mark is 
reached. This should be when there is a point of more resistance when 
depressing the plunger. 
21. Keep the plunger depressed to this point and re-enter the sample drop to 
expel the remaining PBS whilst observing any objects exiting the pipette. 
  
Pipette up and down once or twice with the media in the drop to ensure the 
PB is not stuck to the pipette wall. If the PB can no longer be seen in the 
pipette tip, tightly cap the tube. Move on to the remaining samples repeating 
Steps 12-21. 
 
22. Once all samples have been tubed, briefly centrifuge them to ensure all the 
samples and media are in the bottom of the tubes. 
23. Submerge the bottom of every tube (not the entire tube) in a shallow liquid 
nitrogen bath to snap freeze and store tubes in racks at -200C. 
PAUSE POINT. Samples can be stored at -200C for several days prior to WGA. For 
best results WGA should be performed within 3 days. 
 
Post activation culture. TIMING 16-18hrs 
CRITICAL Ideally, post activation culture should be performed within a time-lapse 
incubator (set to 37°C, 6% CO 2 and 5% O2). This enables easy assessment of PB2 
extrusion and pronuclear formation without having to repeatedly remove oocytes 
from the incubator. It also allows monitoring of embryo development, if using 
embryos instead of activated oocytes. For our protocol we specifically use the 
EmbryoScope system that has its own proprietary dishes (EmbryoSlides), however, 
we also provide below options for proceeding without the use of a time-lapse 
incubator. 
24. After 40 minutes of activation in culture (using samples from Step 9), remove 
the activation culture dish containing the oocytes from the incubator and move 
it to the stereo microscope work station. 
25. Follow option A for post-activation culture using the Embryoscope time-lapse 
incubator, or option B to proceed if a time-lapse incubator is not available: 
A. Post-activation culture using Embryoscope time-lapse incubator 
i) Move each oocyte to a separate well of an EmbryoSlide with a 170um pipette tip. 
Wash using gentle pipetting in the provided wash wells prior to depositing in the final 
post-activation culture micro well (see reagent set-up). CRITICAL STEP: Ensure 
each oocyte is positioned in the centre of the micro-well and that all bubbles are 
removed for best visibility on the time lapse system. 
  
ii) Move the EmbryoSlide to the EmbryoScope incubator unit and insert, following the 
prompts. CRITICAL STEP: It is important that the slide is seated in its position 
securely using substantial downward force.  
 
B. Post-activation culture if time lapse incubator is not available 
i) Move the oocytes to a post-activation dish containing individually labelled 30ul 
drops of post activation culture medium using a 170um stripper. Wash each oocyte 
thoroughly by gentle pipetting in a wash drop within the dish prior to depositing in the 
final culture drop.   
ii) Place the dish in a
 
standard incubator (set at 37°C in 6% CO2 and 5% O2) until 
assessment of PB2 extrusion 16-18 hours after the oocytes are moved to post 
activation culture. ³"7528%/(6+227,1*´ 
 
 
Assessing activation. TIMING 5-10mins 
26.  Follow option A to assess activation using the Embryoscope time-lapse 
incubator, or option B to proceed if a time-lapse incubator is not available: 
A. Assessing activation using Embryoscope time-lapse incubator 
i) After ~ 16 hours of post-activation culture, use the EmbryoScope time lapse viewer 
to scroll through the images of each oocyte whilst the EmryoScope slide containing 
the oocytes remains in the incubator unit. Scrolling at different focal depths may be 
necessary to properly identify PB2 extrusion. Pronuclei may also become visible by 
this time however normal activation is not dependent on it. 
B. Assessing activation if time lapse incubator is not available 
i) After ~ 16 hours of post-activation culture, move the dish containing the oocytes to 
the inverted microscope work station. Gradually focus through the oocytes to identify 
the presence of PB2. Again, pronuclei may also be visible by this time however 
normal activation is not dependent on it. If PB2 is not visible, check again in two 
hours. 
 
PB2 Biopsy. TIMING 15-30mins 
27. Repeat Steps 2-7 to biopsy PB2 observed in step 25  
  
CRITICAL STEP: Ensure extra care is taken when pipetting and that suction with the 
holding pipette (Steps 3-4) avoids the existing aperture in the zona pellucida (Figure 
2B). 
CRITICAL STEP: If PB2 biopsy is to be performed on more than one dish of 
activated oocytes (recommended maximum 6 oocytes per biopsy dish) a second 
operator should perform the tubing procedure below in parallel. 
 
 
PB2 Tubing. TIMING 15-30mins 
28. Repeat steps 12-23 whist the oocyte remains in the drop with the PB2. 
CRITICAL STEP: It is important that the oocyte and PB2 are well separated in 
the drop and that the oocyte is avoided when pipettes enter the drop (steps 
16, 17 & 21) (Figure 2). If working in tandem with another operator, move 
biopsy dish to inverted microscope for zona removal procedure (step 29-32). 
 
PAUSE POINT If working alone, it is possible to leave the biopsy dish, now 
containing only the oocytes (devoid of their PB1 and PB2), on the heated 
stage of the stereo microscope for up to two hours  
 
Zona removal. TIMING 10-20mins 
29. Place the dish containing the oocytes on the inverted microscope (with 
micromanipulators and laser attached) to give a clear view of the zona 
pellucida and secure the oocyte by suction with the holding pipette ensuring 
that the oocyte is just above the bottom of the dish. Be careful to avoid the 
two existing apertures in the zona. 
30. Once in position, make a large aperture in the zona pellucida using a series of 
laser pulses. The aperture should be between a quarter to a half of the zona 
around. Ablate the zona using laser pulses approximately the same diameter 
of the zona thickness, working in a circular fashion (figure 2C).   
31. Insert the aspiration pipette under the zona and gently expel medium to 
displace the oocyte so that it is free from the zona. Ensure that the pipette 
contains sufficient media and be careful not to blow any bubbles. Gentle 
manual manipulation with the aspiration pipette to move the oocyte may also 
be necessary to help the displacement process. 
  
32. Whilst still attached to the zona move the holding pipette to the edge of the 
drop and deposit the zona there leaving the oocyte in the centre of the drop. 
 
Oocyte tubing. TIMING 15-30mins 
33. Repeat steps 12-23 to complete the tubing of the oocyte. CRITICAL STEP: 
avoid the empty zona pellucida when aspirating the oocyte (steps 16-17). 
 
Whole genome amplification (WGA) and SNP genotyping. TIMING: 1-2 days 
CRITICAL: for further details refer to Natesan et. al 20146.  
34. Use a 10ul Gilson pipette to bring the three PCR tubes containing each of the 
trio samples (from steps 20,28 & 33) WRDQHQGYROXPHRIȝOZLWK3%6. 
35. Amplify the DNA  by Multiple displacement amplification (MDA) using a kit 
according to the PDQXIDFWXUHU¶V instructions (SureMDA, Illumina).  
36. Process 400 ng of donor genomic DNA and 8 µl of each of the WGA products 
from the trio samples (PB1, PB2 and oocyte) on SNP genotyping beadchips 
(Human CytoSNP-12 or HumanKaryomap-12 v1.0 BeadChip, Illumina, San 
Diego CA, USA) for ~300K SNPs, following the instructions provided. 
CRITICAL STEP: This step in the protocol can be outsourced to a third party if 
necessary. If so, the samples can be shipped in racks on ice to the 
commissioned laboratory. Do not ship on dry ice. Ensure care is taken with 





Meiomapping. TIMING: 1-2 days or as long as required. 
CRITICAL: Steps 41 [Query to author: Do you mean step 44 here?] onwards are 
carried out using a series of Visual Basic for Applications (VBA) macros in Microsoft 
Excel34. An example data set can be found in Supplementary Data (contact authors 
for further information regarding macros). 
 
37. Import data generated from SNP genotyping into Microsoft Excel and sort 
according to (1) chromosome and (2) base pair (bp) position. Save file and 
archive following step 39. 
  
 
38. Import the SNP genotype data for each of the 23 chromosomes into a second 
Excel spreadsheet for Meiomapping and arrange in columns side-by-side for 
each chromosome and each sample. CRITICAL STEP: Note that the original 
data and processed data are stored in separate Excel workbooks to keep the 
size of the files manageable. 
39. Calculate the call rates and heterozygous call rates for all samples (please 
VHHµ&RPSDULVRQWRRWKHUPHWKRGV¶VHFWLRQIRUGHVFULSWLRQRIFDOOUDWHV. 
40. Select a reference sample (either a PB2 or activated oocyte)  
CRITICAL STEP: Note that to maximise the number of informative SNP loci a 
reference sample with a high call rate and low heterozygous call rate (ADI) should be 
selected. The call rates should exceed 80% although anything above 60% is 
acceptable and the heterozygosity rate should be in the region of 1-2%. 
41. Identify all Informative maternal heterozygous SNP loci genotyped as 
homozygous in the reference sample (AA or BB),  and defined as Maternal 
haplotype 1 (yellow) for each chromosome. See Table 1.  
42. Compare sample genotypes at informative maternal SNP loci for each 
chromosome to the reference genotype and identify as (1) homozygous for 
the same allele ± Maternal haplotype 1 (yellow), (2) homozygous for the other 
allele ± Maternal haplotype 2 (green), (3) heterozygous ± combination of 
Maternal haplotypes 1 and 2 (blue), or (4) no call (grey). See Figure 3 and 
Table 1. See troubleshooting table 3 for explanation of anomalies caused by 
aneuploidy in the reference sample. 
43. Display the results of the previous step as a consecutive series of informative 
SNPs in vertical columns, colour coded with their bp position, for each 
chromosome. Arrange the vertical columns side-by-side for each sample and 
each chromosome (Figure 3). ³"7528%/(6+227,1*´ 
44. Use a macro that detects transitions in maternal haplotypes (based on the 
colour of each cell) or manually annotate the positions of any crossovers 
indicated by the transitions described above For manual annotation, copy and 
  
paste the informative SNPs flanking the recombination into the adjacent right-
hand column, including the colour coding and bp position (Figure 3, enlarged 
region). See troubleshooting table 3 for advice on very closely spaced 
crossovers and for tagging transitions between heterozygous and 
homozygous haploblocks. CRITICAL STEP: Each recombination should 
always be present in two out of three of the products of meiosis at the same 
position. ³"7528%/(6+227,1*´ 
45. Import the flanking SNP positions for each recombination event into a 
separate worksheet. 
 
46. Remove common crossovers from each non-reference sample and add to the 
reference sample (Figure 4). CRITICAL STEP: It is essential to identify and 
remove common crossovers from all other samples and represent them only 
in the reference chromatid. Note that reciprocal recombination between sister 
chromatids in PB2 and the activated oocyte, one of which is the reference, will 
not be visible in the non-reference component either and needs to be added 




47. Calculate the position of all crossovers as an average of the base pair position 
of the two SNPs flanking a crossover. For example, the average of two SNPs 
flanking the crossover shown in the enlarged box in Figure 3 is 39,416,076 
(green SNP position: 39,354,517, yellow SNP position: 39,477,635) and so 
the crossover is inferred to have occurred at position 39,416,076. 
 
48. Correct the haplotype colours across each true recombination following the 
removal of the common crossovers. 
  
 
49. Display the pattern of crossovers in each component of each trio according to 
its position to generate the MeioMap (Figure 4). See troubleshooting table 3 




50. Use further macros within Excel or manual counting to perform secondary 
analysis of the numbers and positions of the crossovers Detect various 
chromosome segregation errors by inferred atypical patterns of homozygous 
and heterozygous regions in the three components in the MeioMap. Please 




- Preparing oocytes: 5 ± 10 minutes (step 1) 
- PB1 biopsy: 15-30 minutes (steps 2-7) 
- Oocyte activation: 45-50 minutes (steps (8-11) 
- PB1 tubing: 15-30 minutes (steps 12-23) 
- Post activation culture: 16 ± 18 hours (overnight; steps 24-25) 
Day Two: 
- Assessing activation: 5 ± 10 minutes (step 26) 
- PB2 biopsy: 15-30 minutes (step 27) 
- PB2 tubing: 15-30 minutes (step 28) 
- Zona removal: 10-20 minutes (step 29-32) 
- Oocyte tubing: 15-30 minutes (step 33) 
- Whole Genome Amplification (WGA) and shipment of samples: ~ 4 hours 
(step 34) 
- Time taken to receive the SNP genotyping results will depend on the 
turnaround time of the service lab.  
Day Three onwards: 
- Meiomapping: The time taken will depend on the number of samples as the 
rate limiting step is the manual annotation of the crossover points, but as a 
guide allow 1-2 full working days. This stage of the protocol is all computer-
















After mapping all of the crossovers genome-wide across all samples the data can be 
represented as a complete MeioMap (Figure 5A) with three columns for each 
chromosome representing the PB1, PB2 and activated oocyte. Note that for any 
given crossover, two out of the three elements are involved (i.e. each crossover is 
reciprocal). Additionally, every haploblock segregates in the predicted Mendelian 
ratios (2 green and 2 yellow chromatids at any given position). In the example 
shown, all chromosomes followed normal meiotic segregation pattern. 
Non-canonical chromosome segregation patterns can also be detected in the 
meiomaps. Examples include reverse segregation where both homologs segregate 
their sister chromatids at meiosis I7, precocious separation of sister chromatids and 
meiosis II non-disjunction (Figure 5B). Note that these non-canonical segregation 
events do not always result in a loss/gain in the oocyte.  
Structural chromosome abnormalities can also be detected in MeioMaps. Frequently 
these are characterised by duplications on one arm of a metacentric chromosome. 
For example, a region of heterozygosity may exist on the q arm of PB1 and on the p 
arm of PB2 or oocyte (as shown in the example in Figure 5C). Structural 
chromosome abnormalities can also manifest as missing segments of a 
chromosome (Figure 5C; bottom)[Query to author: Editor has changed text, please 
check it is OK]. 
The total number of crossovers genome-wide together with the number of 
chromosome segregation errors can be counted for each oocyte-PB trio and used for 
subsequent data analysis. 
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Table 1. Table showing representation of phasing of maternal SNPs in oocyte-PB 
trios and illustrating some of the technical limitations that accompany SNP 
genotyping. Only heterozygous maternal SNPs are informative for phasing. The 
reference sample is from an independent oocyte-trio from the same donor. Where 
the sample SNP matches the reference (light pink) it is assigned maternal haplotype 
1 and is colored yellow in the MeioMap. Where the sample SNP differs from the 
reference, it is assigned maternal haplotype 2 and colored green. Where both SNPs 
are present (AB) the region is heterozygous and is colored blue in the MeioMap. 
When neither SNP calls, the SNP is colored grey. Crossovers between homozygous 
regions of PB2 and oocyte occurs at SNP 6 as detected by a switch from yellow to 
green SNPs (and vice versa). A crossover between heterozygous and homozygous 
  
regions in PB1 and oocyte, respectively RFFXUVDW613$µFRPPRQFURVVRYHU¶
(see Development of Protocol & Figure 4) occurs at SNP 14. Allele Drop Out (ADO) 
refers to when one SNP of a particular haplotype fails to call. If this occurs within a 
EORFNRIKRPR]\JRVLW\WKLVZLOOPDQLIHVWDVDµQRFDOO¶ZKHUHQHLWKHUKDSORW\SHLV
present for that particular SNP. In contrast, ADO in an otherwise heterozygous block 
will manifest as only one haplotype being present for that particular SNP (e.g. one 
green cell surrounded by a block of blue cells either side). Allele Drop In (ADI) refers 
to when the opposing haplotype calls for one particular SNP in an otherwise 
homozygous region (e.g. one blue cell surrounded by a block of green or yellow cells 
either side). Examples of allele drop out (ADO) and allele drop in (ADI) are as 
follows: ADO in homozygous region (grey cell, SNP 4 PB2) leads to loss of 
resolution; ADO in heterozygous region (SNP 4 or 9 in PB1) leads to loss of 
heterozygosity and creaWHVµQRLVH¶LQWKHGDWD'RXEOH$'2613LQ3%UHVXOWVLQ
no call and a reduced resolution; ADI without ADO (SNP 13 in PB2) results in 
HUURQHRXVKHWHUR]\JRXVFDOOVDQGµQRLVH¶LQWKHGDWD$',ZLWK accompanying ADO 














Table 2. The relationship between the number of oocyte-PB trios per donor and the 




Crossovers detected and assigned 
1 
All crossovers between homologous chromosomes detected but 
cannot be assigned to the specific chromatid in PB2 or oocyte. 
Meiomapping cannot detect crossovers occurring within 
heterozygous regions of the chromosome remaining in PB1. 
 
2 All crossovers between homologous chromosomes detected and 
assigned to PB2 or oocyte in non-reference trio. 
  
Crossovers between sister chromatids in PB2 and oocyte are 
detected but cannot be assigned to a specific trio. Repeating the 
meiomap analysis with the reference in the second trio allows 
assignment in both trios 
 
Ӌ3 
All crossovers between homologous chromosomes detected and 
assigned to PB2 or oocyte in all trios. Repeating the meiomap 
analysis with a second reference in a different trio allows 
complete assignment in the original ref trio and the other trios 







Table 3:  Troubleshooting table 
  
Step 
No. Problem Possible Reason Possible Solution 
2 
Fragmentation 
of the polar 
bodies. 
Biopsy taking place too 
long after polar body 
extrusion. 
If fragmentation occurs, try to 
extract and tube all 
fragments and make a note 
of the sample that can be 
referred back to if any non-
mendelian losses or gains 
are observed. Performing the 
biopsy immediately after 
polar body extrusion should 






Calcium ionophore not 
fully solubilised in stock 
solution. 
Ensure calcium ionophore is 
fully solubilised in DMSO 
when preparing stock 
solution. 
36 Poor DNA 
amplification. 
DNA may have partially 
degraded. 
Keep samples on ice and 
tubes capped whenever 
possible to minimise 
exposure to nucleases. You 
can confirm the DNA 
amplification step by running 









loss or gain) in the 
reference sample. 
Aneuploidy in the reference 
requires that you use an 
alternative reference for that 
chromosome only. This 
should restore the normal 






give rise to very 
short haplotype 
blocks (1). 
These could be genuinely 
closely spaced crossovers 
(see below). Alternatively, 
they may be a crossover 
very close to a common 
crossover. In the rare 
event that a crossover 
occurs at the exact same 
SNP position as a 
common crossover, this 
will render the common 
crossover invisible in this 
sample.  
 
If this is caused by proximity 
to a common crossover, this 
should be apparent from 
presence of the common 
crossover across all 
samples. 
 
If a crossover occurs at the 
exact same position to a 
common crossover in the 
reference this will be 
detectable by the common 
FURVVRYHUµPLVVLQJ¶IURPRQH
sample. In this scenario, it 
  
becomes advantageous to 
have multiple samples from 
the same donor in order to 
expose the sample with the 
µPLVVLQJ¶FRPPRQFURVVRYHU 
 
In either case, the true 
pattern of crossovers can be 
confirmed by using an 






give rise to very 
short haplotype 
blocks (2). 
Although crossovers are 
generally widely spaced 
(owing to crossover 
interference), sometimes 
two crossovers can occur 
in close proximity. 
It is therefore worth setting 
the minimum number of 
consecutive SNPs that are 
required to define a 
haploblock. This is also 
applicable to crossovers that 
occur very close to 
telomeres. If allele drop in 
(ADI) rates are particularly 
high you may want to 
increase the threshold of 










Regions of heterozygosity 
indicate the presence of 
two non-sister chromatids, 
typically in PB1, tend to 
have variable levels of 
DOOHOHGURSRXWDQGµQR
FDOOV¶7DEOH7KLVPD\
make it hard to judge 
ZKHUHWRµWDJ¶WKHODVW
SNP of the heterozygous 
block. 
 
The nearest available 
heterozygous (blue) SNP to 
the crossover should 
therefore be tagged along 
with the first available SNP of 
the next haplotype (yellow or 
green).The reciprocal 
transition in PB2 or the 
activated oocyte can be used 
to align the precise position 








Large regions of repetitive 
sequences surround the 
centromeres of both 
chromosomes 1 and 9 
and are therefore absent 
from the SNP array. 
Since crossovers cannot be 
mapped directly in these 
regions be aware of 
haplotype switches either 
side of the centromere, 
which would indicate a 
crossover somewhere in this 
µEOLQG¶UHJLRQZKLFKFDQEH
arbitrarily assigned to either 






Figure 1. Schematic showing an adult oocyte completing the first and second 
meiotic divisions. In the adult ovary, primary oocytes contain 23 pairs of homologous 
FKURPRVRPHVKHOGWRJHWKHUE\FURVVRYHUVLQWKHµELYDOHQW¶FRQILJXUDWLRQ2RF\WHV
complete meiosis I in vivo and extrude one set of homologs into the first polar body 
(PB1), the mature oocyte then arrests at metaphase II. Completion of meiosis II 
normally only occurs upon fertilisation, but we utilise a calcium ionophore to trigger 
meiosis II without fertilisation by sperm. At meiosis II one pair of sister chromatids 
are extruded to the second polar body (PB2) resulting in a haploid oocyte.  
 
Figure 2. Images showing oocyte activation and sequential biopsy of first and 
second polar bodies. (A) The first polar body (PB1) is biopsied and tubed (µSRODU
ERG\ELRSV\¶steps 11-22). (B) The mature oocyte is then activated using a 
calcium ionophore and the second polar body (PB2) is then biopsied µSRODUERG\
ELRSV\¶VWHSV-30). Note the appearance of a pronucleus in the activated oocyte 
(black arrow). The position of the laser is shown by a red cross within a green circle. 
(C) Finally, the activated oocyte is isolated from the zona pellucida, ready for tubing 
(steps 31-32). Bars: 15 µm.  Permission to perform this experiment was obtained 
from the Ethical Review board at GENERA clinic, Italy.   
 
 
Figure 3. Screenshot of SNP patterns in a MeioMap showing a region of a single 
chromosome across an oocyte-polar body trio. Each cell represents the position of a 
single SNP and opposing maternal SNPs are shown as yellow or green cells. When 
both sets of maternal SNPs are present (i.e. in heterozygous regions), the cells are 
coloured blue. Grey cells denote SNPs that have failed to call (ADO). Transitions 
between haSORW\SHVPDUNSRLQWVRIFURVVRYHUV&URVVRYHUVDUHµWDJJHG¶VWHS44) by 
copying the two SNPs flanking a crossover into the right-hand adjacent column. The 
red dashed box illustrates where a crossover has occurred in the reference resulting 
LQDµFRPPRQFURVVRYHU¶DWWKHVDPHSRVLWLRQDFURVVDOOKRPR]\JRXVVDPSOHVThe 
boxed area is enlarged on the right to show the SNP positions in each cell. In this 
example the SNPs flanking the crossover are 123 kb apart. Screenshot is from data 
imported into a Microsoft Excel worksheet. [MPS: It is not necessary to be able to 
read the specific numbers on the right of this figure.] 
  
 
Figure 4.  Informative SNPs are phased using a reference chromatid to reveal 
positions of haplotype switches (crossovers). (A) A haploid cell containing a single 
chromatid (either PB2 or Oocyte) with a good call rate is chosen as the reference 
chromatid. Oocyte-PB trios from the same individual are compared to the reference 




homozygous samples at the same position (dotted red boxes). (B) These common 
crossovers are identified, removed and replaced to the reference chromatid using a 
macro. This process is repeated with a second reference to confirm crossover 
positions and the original ancestral phase of the two maternal haplotypes (C). 
 
Figure 5. Anticipated results of Meiomapping. (A) An example of a complete 
Meiomap of an oocyte-PB trio. The three columns correspond to polar body 1 (PB1), 
polar body 2 (PB2) and oocyte. Green and yellow maternal haplotypes are shown 
and where both are present (in PB1) this is represented in blue. Regions where 
SNPs are not available on the array are shown in white (centromeres of 
chromosomes 1 and 9) or gray (rDNA). Black boxes indicate the centromeres. (B) 
Three example meiomaps (of a single chromosome) following non-canonical 
chromosome segregation patterns. This includes reverse segregation where both 
homologs segregate their sister chromatids at meiosis I, characterised by a PB1 with 
heterozygous SNPs (blue) around the centromere7. In the example of precocious 
separation of sister chromatids, an extra chromatid segregated into the PB1 with a 
corresponding loss in PB2. Meiosis II non-disjunction is characterised by a normal 
PB1 (two chromatids homozygous at the centromere) but with a gain and 
corresponding loss in the PB2/oocyte. Schematic representations of the inferred 
patterns of chromosome segregation shown to the right. (C) Two examples of 
structural chromosome rearrangements. Top example; an extra segment from the p-
arm of chromosome 8 segregated to the oocyte. Bottom example; a large segment 
of the q-arm of chromosome 22 is missing in the oocyte. Schematic representations 
of the inferred patterns of chromosome segregation shown to the right. 
 
Supplementary Data 
An example Excel spreadsheet containing the raw data and assimilated MeioMap for 
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Crossover in reference chromatid 
shows up as a common crossover 








PB1 PB2 Egg PB1PB2 Egg PB1 PB2 Egg
Trio1 Trio2 Trio3
PB1 PB2 Egg PB1 PB2 Egg PB1 PB2 Egg
Trio1 Trio2 Trio3
Infer
crossovers
on reference
 chromatid
Maternal
Haplotype 
1
A
T
G
T
C
T
A
A
G
T
A
G
C
C
C
C
A
C
T
C
C
C
A
G
G
T
A
A
Maternal
Haplotype 
2
A/C
T/C
G/A
T/C
C/T
T/C
A/C
A/C
G/A
T/G
A/G
G/T
C/A
C/A
Unphased
 maternal 
SNPs
Phased 
ancestor
